par Bidard, François-Clément;Peeters, Dieter;Fehm, Tanja;Nolé, Franco;Gisbert-Criado, Rafael;Mavroudis, Dimitris;Grisanti, Salvatore;Generali, Daniele;Garcia-Saenz, Jose JA;Stebbing, Justin;Caldas, Carlos;Gazzaniga, Paola;Manso, Luis;Zamarchi, Rita;de Lascoiti, Angela Fernandez;de Mattos-Arruda, Letícia;Ignatiadis, Michail ;Lebofsky, Ronald;Van Laere, Steven;Meier-Stiegen, Franziska;Sandri, Maria Teresa;Vidal-Martinez, Jose;Politaki, Eleni;Consoli, Francesca;Bottini, Alberto;Díaz-Rubio, Eduardo;Krell, Jonathan;Dawson, Sarah Jane;Raimondi, Cristina;Rutten, Annemie;Janni, Wolfgang;Munzone, Elisabetta;Carañana, Vicente;Agelaki, Sofia;Almici, Camillo;Dirix, Luc Y;Solomayer, Erich-Franz;Zorzino, Laura;Johannes, Helene;Reis-Filho, Jorge Sergio;Pantel, Klaus;Pierga, Jean-Yves;Michiels, Stefan
Référence Lancet oncology, 15, 4, page (406-414)
Publication Publié, 2014-04
Référence Lancet oncology, 15, 4, page (406-414)
Publication Publié, 2014-04
Article révisé par les pairs
Résumé : | We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data. |